Eli Lilly stock soars on strong demand for weight loss drugs

What happened: Eli Lilly (LLY) stock jumped arsenic overmuch arsenic 7% connected Wednesday.

What's down the move: The cause institution raised its 2026 income forecast aft it saw beardown request for GLP-1 drugs successful its fiscal 2nd quarter.

Revenue is present expected to autumn betwixt $85 cardinal and $87 cardinal for the year, topping an earlier forecast of up to $85 billion, according to Bloomberg data.

Adjusted net for the 2nd 4th besides bushed Wall Street estimates.

What other you request to know: Eli Lilly's GLP-1 concern has been the maturation motor of the cause company, benefiting from respective tailwinds since the commencement of the year, including the FDA's support of Foundayo, the pill mentation of its weight-loss drug, earlier this year.

The institution is besides processing next-generation weight-loss medicine retatrutide. It has objective information successful manus and plans to record for FDA support successful the archetypal 4th of adjacent year.

Shares of the drugmaker person rebounded from a archetypal 4th slump, with the banal climbing much than 40% since the extremity of April and gaining 3% twelvemonth to date, according to Yahoo Finance AlphaSpace data.

Ines Ferre is simply a Senior Business Reporter for Yahoo Finance covering the US banal market, publically traded companies, and commodities. She has reported unrecorded from the level of the New York Stock Exchange and Nasdaq. Follow her connected X astatine @ines_ferre.

Click present for the latest trending banal tickers connected the Yahoo Finance platform.